Cannabis Campaigners' Guide News Database result:


After you have finished reading this article you can click here to go back.

Marijuana may block Alzheimer's

BBC Online

Tuesday 22 Feb 2005

---

The active ingredient in marijuana may stall decline from Alzheimer's
disease, research suggests.

Scientists showed a synthetic version of the compound may reduce
inflammation associated with Alzheimer's and thus help to prevent mental
decline.

They hope the cannabinoid may be used to developed new drug therapies.

The research, by Madrid's Complutense University and the Cajal Institute,
is published in the Journal of Neuroscience.

The scientists first compared the brain tissue of patients who died from
Alzheimer's disease with that of healthy people who had died at a similar age.

They looked closely at brain cell receptors to which cannabinoids bind,
allowing their effects to be felt.

They also studied structures called microglia, which activate the brain's
immune response.

Microglia collect near the plaque deposits associated with Alzheimer's
disease and, when active, cause inflammation.

The researchers found a dramatically reduced functioning of cannabinoid
receptors in diseased brain tissue.

This was an indication that patients had lost the capacity to experience
cannabinoids' protective effects.

The next step was to test the effect of cannabinoids on rats injected with
the amyloid protein that forms Alzheimer's plaques.

Those animals who were also given a dose of a cannabinoid performed much
better in tests of their mental functioning.

The researchers found that the presence of amyloid protein in the rats'
brains activated immune cells.

However, rats that also received the cannabinoid showed no sign of
microglia activation.

Using cell cultures, the researchers confirmed that cannabinoids
counteracted the activation of microglia and thus reduced inflammation.

Drug target

Researcher Dr Maria de Ceballos said: "These findings that cannabinoids
work both to prevent inflammation and to protect the brain may set the
stage for their use as a therapeutic approach for Alzheimer's disease."

Dr Susanne Sorensen, head of research at the Alzheimer's Society, said:
"This is important research because it provides another piece of the jigsaw
puzzle on the workings of the brain.

"There is no cure for Alzheimer's disease, so the identification of another
target for drug development is extremely welcome.

"The Alzheimer's Society looks forward to seeing further research being
carried out on cannabinoid receptors as drug targets for Alzheimer's
disease but would warn the public against taking marijuana as a way of
preventing Alzheimer's.

"It is now generally recognised that as well as providing a 'high',
long-term use of marijuana can also lead to depression in many individuals."

Different receptors

Harriet Millward, of the Alzheimer's Research Trust, said there were two
main types of cannabinoid receptor, CR1 and CR2.

"It is CR1 that produces most of the effects of marijuana, including the
harmful ones.

"If it is possible to make drugs that act only on CR2, as suggested by the
authors of this study, they might mimic the positive effects of
cannabinoids without the damaging ones of marijuana.

"However, this is a fairly new field of research and producing such
selective drugs is not an easy task.

"There is also no evidence yet that cannabinoid-based drugs can slow the
decline in human Alzheimer's patients."


 

 

 

After you have finished reading this article you can click here to go back.




This page was created by the Cannabis Campaigners' Guide.
Feel free to link to this page!